

28<sup>th</sup> September, 2024

**BSE Limited**

P.J. Towers, Dalal Street, Fort,  
Mumbai- 400 001  
BSE scrip code: 543635

**National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400 051  
NSE symbol: PPLPHARMA

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Receipt of Establishment Inspection Report ('EIR') with respect to US FDA Inspection at Piramal Pharma's manufacturing facility located at Ahmedabad, India**

Dear Sir / Madam,

Kindly refer to our letter dated 12<sup>th</sup> July, 2024 regarding US FDA Inspection at Piramal Pharma Limited's manufacturing facility located at Ahmedabad, India, with Zero Form - 483 observations and No Action Indicated (NAI) designation.

In furtherance to the aforementioned intimation, this is to inform you that US FDA has issued an EIR for the said manufacturing facility.

Receipt of said EIR marks formal closure of the inspection.

This is for your information and records.

Thanking you,

Yours truly,

For **Piramal Pharma Limited**

**Tanya Sanish**  
Company Secretary

**Piramal Pharma Limited**

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India

T +91 22 3802 3000 / 4000

[Piramalpharma.com](http://Piramalpharma.com)